Accounts Receivable, after Allowance for Credit Loss, Current of CRESCENT BIOPHARMA, INC. from 30 Jun 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
CRESCENT BIOPHARMA, INC. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 30 Jun 2015 to 31 Dec 2025.
  • CRESCENT BIOPHARMA, INC. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Dec 2025 was $18,000,000.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)

CRESCENT BIOPHARMA, INC. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $18,000,000 +$18,000,000 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q4 2024 $0 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q2 2015 $20,000,000 30 Jun 2015 10-Q 06 Aug 2015 2015 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.